Pub Date : 2025-12-01DOI: 10.1016/j.reuma.2025.501990
Susana Romero-Yuste , Manuel Macía , Marta Domínguez-Álvaro , Antonio Fernández-Nebro , Miquel Blasco , Javier Narváez , Gema Fernández , Íñigo Rúa-Figueroa , Desirée Luis-Rodríguez , Beatriz Ventosa , en representación del Grupo colaborador del proyecto RESER/NVAN
Objective
To describe the objectives, design and methods of the Spanish Multicentre Registry of Patients with ANCA-associated Vasculitis (RESER/NVAN), as well as its strengths and limitations. RESER/NVAN is a project promoted by the Spanish Society of Rheumatology, in collaboration with the Spanish Society of Nephrology, whose main objective is to estimate the incidence of ANCA-associated vasculitis in Spain.
Methods
Retrospective longitudinal observational study of ANCA-associated vasculitis patients ≥18 years of age diagnosed between 1 January 2015 and 31 March 2021. All patients in the reference area of each centre were included, with the reference area being the area that includes the population attended by the centre. Thirty-two centres distributed throughout the Spanish geography participated, and the administrative and/or clinical databases of each centre and those of the services that could be involved in the diagnosis and/or treatment of these patients were reviewed. Sociodemographic and anthropometric variables, lifestyle habits, comorbidities and variables characterising vasculitis were collected.
Conclusions
RESER/NVAN represents one of the largest cohorts of patients with ANCA-associated vasculitis in Spain. Despite its retrospective nature, the study provides comprehensive and reliable information on ANCA-associated vasculitis and is an excellent source of data for future analyses to increase knowledge of this disease.
{"title":"RESER/NVAN: registro español de pacientes con vasculitis asociadas a ANCA: objetivos y metodología","authors":"Susana Romero-Yuste , Manuel Macía , Marta Domínguez-Álvaro , Antonio Fernández-Nebro , Miquel Blasco , Javier Narváez , Gema Fernández , Íñigo Rúa-Figueroa , Desirée Luis-Rodríguez , Beatriz Ventosa , en representación del Grupo colaborador del proyecto RESER/NVAN","doi":"10.1016/j.reuma.2025.501990","DOIUrl":"10.1016/j.reuma.2025.501990","url":null,"abstract":"<div><h3>Objective</h3><div>To describe the objectives, design and methods of the Spanish Multicentre Registry of Patients with ANCA-associated Vasculitis (RESER/NVAN), as well as its strengths and limitations. RESER/NVAN is a project promoted by the Spanish Society of Rheumatology, in collaboration with the Spanish Society of Nephrology, whose main objective is to estimate the incidence of ANCA-associated vasculitis in Spain.</div></div><div><h3>Methods</h3><div>Retrospective longitudinal observational study of ANCA-associated vasculitis patients ≥18 years of age diagnosed between 1 January 2015 and 31 March 2021. All patients in the reference area of each centre were included, with the reference area being the area that includes the population attended by the centre. Thirty-two centres distributed throughout the Spanish geography participated, and the administrative and/or clinical databases of each centre and those of the services that could be involved in the diagnosis and/or treatment of these patients were reviewed. Sociodemographic and anthropometric variables, lifestyle habits, comorbidities and variables characterising vasculitis were collected.</div></div><div><h3>Conclusions</h3><div>RESER/NVAN represents one of the largest cohorts of patients with ANCA-associated vasculitis in Spain. Despite its retrospective nature, the study provides comprehensive and reliable information on ANCA-associated vasculitis and is an excellent source of data for future analyses to increase knowledge of this disease.</div></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"21 10","pages":"Article 501990"},"PeriodicalIF":1.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145645939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-01DOI: 10.1016/j.reuma.2025.502017
Ayfer Altıntas , Emre Ali Acar , Sadettin Uslu , Ihsan Sebnem Orgüc , Zeliha Hekimsoy , Timur Pirildar
Objective
To investigate the frequency of diffuse idiopathic skeletal hyperostosis (DISH) in patients with prediabetes.
Material and methods
A total of 166 prediabetic patients were prospectively evaluated, of whom 67 with symptoms suggestive of DISH underwent thoracic and lumbar radiography. DISH was diagnosed according to Resnick and Niwayama criteria. Demographic, clinical and laboratory data were analyzed.
Results
DISH was diagnosed in 9 patients (13.4% of symptomatic; 5.4% overall). Patients with DISH were older and more frequently hypertensive compared to those without DISH (p = 0.004 and p = 0.047, respectively). Other parameters such as body mass index, fasting glucose, and smoking showed higher trends in the DISH group but did not reach statistical significance.
Conclusion
This is the first study to examine DISH in a prediabetic population. Our findings suggest a possible association between DISH and prediabetic status, although further studies are needed to confirm this relationship.
{"title":"Diffuse idiopathic skeletal hyperostosis in patients with prediabetes","authors":"Ayfer Altıntas , Emre Ali Acar , Sadettin Uslu , Ihsan Sebnem Orgüc , Zeliha Hekimsoy , Timur Pirildar","doi":"10.1016/j.reuma.2025.502017","DOIUrl":"10.1016/j.reuma.2025.502017","url":null,"abstract":"<div><h3>Objective</h3><div>To investigate the frequency of diffuse idiopathic skeletal hyperostosis (DISH) in patients with prediabetes.</div></div><div><h3>Material and methods</h3><div>A total of 166 prediabetic patients were prospectively evaluated, of whom 67 with symptoms suggestive of DISH underwent thoracic and lumbar radiography. DISH was diagnosed according to Resnick and Niwayama criteria. Demographic, clinical and laboratory data were analyzed.</div></div><div><h3>Results</h3><div>DISH was diagnosed in 9 patients (13.4% of symptomatic; 5.4% overall). Patients with DISH were older and more frequently hypertensive compared to those without DISH (<em>p</em> <!-->=<!--> <!-->0.004 and <em>p</em> <!-->=<!--> <!-->0.047, respectively). Other parameters such as body mass index, fasting glucose, and smoking showed higher trends in the DISH group but did not reach statistical significance.</div></div><div><h3>Conclusion</h3><div>This is the first study to examine DISH in a prediabetic population. Our findings suggest a possible association between DISH and prediabetic status, although further studies are needed to confirm this relationship.</div></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"21 10","pages":"Article 502017"},"PeriodicalIF":1.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145645937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-01DOI: 10.1016/j.reuma.2025.501993
Carlos Valera-Ribera , Juan José Alegre-Sancho , Àngels Martínez-Ferrer , Montserrat Robustillo-Villarino
Objectives
To describe the prevalence of sexual dysfunction (SD) in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and a control group, and identify associated factors.
Methods
Adults of any sexual orientation with PsA (CASPAR criteria) or RA (EULAR/ACR 2010 criteria) were consecutively included in this cross-sectional observational study. The Changes in Sexual Functioning Questionnaire (CSFQ-14) was self-administered to evaluate variations in sexual function due to disease or medication. We also evaluated the potential association of sociodemographic and clinical data with SD. Results were compared with a control group of healthy individuals.
Results
Overall 188 individuals were included, 72 with PsA and 27 with RA. In total, 30.43%, 48.15% and 5.88% of the PsA, RA and control groups, respectively, had scores within the SD range. The overall patient population had a mean CSFQ-14 score 8.2 points lower than the control group. All domains of the CSFQ-14 questionnaire were negatively affected by PsA or RA (p < 0.001). The risk of SD is associated with age, sex, perceived health, employment situation, and economic status. The estimated odds ratio of having SD was 8.7 times higher in patients diagnosed with PsA and 10 times higher in patients diagnosed with RA.
Conclusions
Patients with RA or PsA have a poorer sexual life in all sexual sphere domains, compared to a healthy population. Our study confirms the value of the CSFQ-14 questionnaire for assessing sexual health and as a tool for the integral management of patients with chronic joint diseases.
{"title":"Prevalence and impact of chronic joint diseases on the sexual sphere compared to a healthy population: A multicenter cross-sectional study","authors":"Carlos Valera-Ribera , Juan José Alegre-Sancho , Àngels Martínez-Ferrer , Montserrat Robustillo-Villarino","doi":"10.1016/j.reuma.2025.501993","DOIUrl":"10.1016/j.reuma.2025.501993","url":null,"abstract":"<div><h3>Objectives</h3><div>To describe the prevalence of sexual dysfunction (SD) in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and a control group, and identify associated factors.</div></div><div><h3>Methods</h3><div>Adults of any sexual orientation with PsA (CASPAR criteria) or RA (EULAR/ACR 2010 criteria) were consecutively included in this cross-sectional observational study. The Changes in Sexual Functioning Questionnaire (CSFQ-14) was self-administered to evaluate variations in sexual function due to disease or medication. We also evaluated the potential association of sociodemographic and clinical data with SD. Results were compared with a control group of healthy individuals.</div></div><div><h3>Results</h3><div>Overall 188 individuals were included, 72 with PsA and 27 with RA. In total, 30.43%, 48.15% and 5.88% of the PsA, RA and control groups, respectively, had scores within the SD range. The overall patient population had a mean CSFQ-14 score 8.2 points lower than the control group. All domains of the CSFQ-14 questionnaire were negatively affected by PsA or RA (<em>p</em> <!--><<!--> <!-->0.001). The risk of SD is associated with age, sex, perceived health, employment situation, and economic status. The estimated odds ratio of having SD was 8.7 times higher in patients diagnosed with PsA and 10 times higher in patients diagnosed with RA.</div></div><div><h3>Conclusions</h3><div>Patients with RA or PsA have a poorer sexual life in all sexual sphere domains, compared to a healthy population. Our study confirms the value of the CSFQ-14 questionnaire for assessing sexual health and as a tool for the integral management of patients with chronic joint diseases.</div></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"21 10","pages":"Article 501993"},"PeriodicalIF":1.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145645941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-01DOI: 10.1016/j.reuma.2025.501974
Adriana Lucía Vanegas-García , Mauricio Restrepo-Escobar , Álvaro Arbeláez-Cortés , Gina Sicilia Ochoa Galeano , Luis Lira Weldt , Guillermo Andrés Quiceno , Virginia Pascual-Ramos
Background
Shared decision-making (SDM) has been linked to improved patient- and physician-reported outcomes. To achieve these benefits, both parties need to agree on implementing SDM. The objective of the study was to compare the perception of SDM process implementation in daily practice between patients with rheumatic diseases (RMDs) and rheumatologists.
Methods
This cross-sectional study was conducted in April 2024 in Latin America (LATAM). Adult patients diagnosed with RMDs and rheumatologists were invited to participate in a web-based survey based on the Spanish patient version of the 9-item SDM questionnaire (SDM-Q-9) and the physician version (SDM-Q-Doc). Both versions were validated tools for evaluating patients’ and physicians’ perceived levels of SDM. Descriptive statistics and comparative tests (e.g., chi-square or Mann–Whitney U test) were used to analyze the data. Statistical significance was set at p < 0.05, and analyses were conducted using STATA 17 software.
Results
We received surveys from 369 patients, primarily systemic lupus erythematosus (51.8%) and rheumatoid arthritis (19.5%), across 17 countries. The largest number of responses was from Mexico (42%) and Colombia (11.9%). The survey was completed by 144 rheumatologists from 10 countries, primarily from Colombia (52.8%) and Chile (23.6%). Physicians most frequently strongly agree/agree that they engaged in the different steps of the SDM process, compared to patients, and this difference was less evident for the step “sharing with the patient the different options for treating the condition.” Also, a higher percentage of rheumatologists (96.5%) reported engaging in SDM during clinical practice compared to patients (62.3%), p = 0.001.
Conclusions
In LATAM, rheumatologists more frequently referred to implementing the SDM process during clinical care than patients with RMDs. Further research is needed to improve patient-centered care.
{"title":"Patients’ and rheumatologists’ perceptions about shared decision-making implementation: A Latin-American survey","authors":"Adriana Lucía Vanegas-García , Mauricio Restrepo-Escobar , Álvaro Arbeláez-Cortés , Gina Sicilia Ochoa Galeano , Luis Lira Weldt , Guillermo Andrés Quiceno , Virginia Pascual-Ramos","doi":"10.1016/j.reuma.2025.501974","DOIUrl":"10.1016/j.reuma.2025.501974","url":null,"abstract":"<div><h3>Background</h3><div>Shared decision-making (SDM) has been linked to improved patient- and physician-reported outcomes. To achieve these benefits, both parties need to agree on implementing SDM. The objective of the study was to compare the perception of SDM process implementation in daily practice between patients with rheumatic diseases (RMDs) and rheumatologists.</div></div><div><h3>Methods</h3><div>This cross-sectional study was conducted in April 2024 in Latin America (LATAM). Adult patients diagnosed with RMDs and rheumatologists were invited to participate in a web-based survey based on the Spanish patient version of the 9-item SDM questionnaire (SDM-Q-9) and the physician version (SDM-Q-Doc). Both versions were validated tools for evaluating patients’ and physicians’ perceived levels of SDM. Descriptive statistics and comparative tests (e.g., chi-square or Mann–Whitney <em>U</em> test) were used to analyze the data. Statistical significance was set at <em>p</em> <!--><<!--> <!-->0.05, and analyses were conducted using STATA 17 software.</div></div><div><h3>Results</h3><div>We received surveys from 369 patients, primarily systemic lupus erythematosus (51.8%) and rheumatoid arthritis (19.5%), across 17 countries. The largest number of responses was from Mexico (42%) and Colombia (11.9%). The survey was completed by 144 rheumatologists from 10 countries, primarily from Colombia (52.8%) and Chile (23.6%). Physicians most frequently strongly agree/agree that they engaged in the different steps of the SDM process, compared to patients, and this difference was less evident for the step “sharing with the patient the different options for treating the condition.” Also, a higher percentage of rheumatologists (96.5%) reported engaging in SDM during clinical practice compared to patients (62.3%), <em>p</em> <!-->=<!--> <!-->0.001.</div></div><div><h3>Conclusions</h3><div>In LATAM, rheumatologists more frequently referred to implementing the SDM process during clinical care than patients with RMDs. Further research is needed to improve patient-centered care.</div></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"21 10","pages":"Article 501974"},"PeriodicalIF":1.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145645938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-01DOI: 10.1016/j.reuma.2025.501997
Olga Rusinovich-Lovgach , Luz Morán , Oscar Toldos-Gonzalez , Marta Vaquero Martínez , Borja Cabal-Paz , José Luis Andréu Sánchez
We describe a young man with persistent hyperCKemia and MRI findings initially suggestive of inflammatory myopathy, in whom genetic testing confirmed Bethlem myopathy. This case illustrates how collagen VI-related myopathies can mimic idiopathic inflammatory myopathies (IIM), underlining the need for integrated clinical, imaging, biopsy, and genetic data to ensure diagnostic accuracy and avoid unnecessary immunosuppression.
{"title":"Diagnostic challenge: Bethlem myopathy mimicking inflammatory myopathy","authors":"Olga Rusinovich-Lovgach , Luz Morán , Oscar Toldos-Gonzalez , Marta Vaquero Martínez , Borja Cabal-Paz , José Luis Andréu Sánchez","doi":"10.1016/j.reuma.2025.501997","DOIUrl":"10.1016/j.reuma.2025.501997","url":null,"abstract":"<div><div>We describe a young man with persistent hyperCKemia and MRI findings initially suggestive of inflammatory myopathy, in whom genetic testing confirmed Bethlem myopathy. This case illustrates how collagen VI-related myopathies can mimic idiopathic inflammatory myopathies (IIM), underlining the need for integrated clinical, imaging, biopsy, and genetic data to ensure diagnostic accuracy and avoid unnecessary immunosuppression.</div></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"21 10","pages":"Article 501997"},"PeriodicalIF":1.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145645521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-01DOI: 10.1016/j.reuma.2025.501995
Wilmer Gerardo Rojas-Zuleta, Yesith Guillermo Toloza-Pérez, Carolina Becerra Arias, Jorge Donado Gómez, Jeixa Jennifer Canizales Rodríguez, Oscar Jair Felipe Díaz
Introduction
Rheumatoid arthritis is associated with an increased risk of chronic kidney disease, which complicates the safe use of disease-modifying antirheumatic drugs, particularly in patients with severe renal impairment. Our aim was to describe treatment patterns and clinical outcomes in this population.
Methods
Descriptive study of a cohort of rheumatoid arthritis patients with an estimated glomerular filtration rate < 30 ml/min/1.73 m2, managed in a comprehensive care program between 2022 to 2024. Clinical, therapeutic, and safety data were collected.
Results
A total of 38 patients were identified, most of whom were elderly women with a high burden of comorbidities. Leflunomide was the most frequently used conventional synthetic disease-modifying antirheumatic drug. Biologic therapy was used in 42% of cases, with rituximab being the most commonly prescribed agent. Most patients achieved remission or low disease activity, with no serious adverse events reported.
Conclusions
These findings provide real-world evidence on the effectiveness and safety of disease-modifying antirheumatic drugs in a population often excluded from clinical trials, underscoring the need for prospective studies to inform long-term therapeutic decisions.
{"title":"Tratamiento de la artritis reumatoide en pacientes con enfermedad renal crónica: una experiencia de vida real","authors":"Wilmer Gerardo Rojas-Zuleta, Yesith Guillermo Toloza-Pérez, Carolina Becerra Arias, Jorge Donado Gómez, Jeixa Jennifer Canizales Rodríguez, Oscar Jair Felipe Díaz","doi":"10.1016/j.reuma.2025.501995","DOIUrl":"10.1016/j.reuma.2025.501995","url":null,"abstract":"<div><h3>Introduction</h3><div>Rheumatoid arthritis is associated with an increased risk of chronic kidney disease, which complicates the safe use of disease-modifying antirheumatic drugs, particularly in patients with severe renal impairment. Our aim was to describe treatment patterns and clinical outcomes in this population.</div></div><div><h3>Methods</h3><div>Descriptive study of a cohort of rheumatoid arthritis patients with an estimated glomerular filtration rate<!--> <!--><<!--> <!-->30<!--> <!-->ml/min/1.73<!--> <!-->m<sup>2</sup>, managed in a comprehensive care program between 2022 to 2024. Clinical, therapeutic, and safety data were collected.</div></div><div><h3>Results</h3><div>A total of 38 patients were identified, most of whom were elderly women with a high burden of comorbidities. Leflunomide was the most frequently used conventional synthetic disease-modifying antirheumatic drug. Biologic therapy was used in 42% of cases, with rituximab being the most commonly prescribed agent. Most patients achieved remission or low disease activity, with no serious adverse events reported.</div></div><div><h3>Conclusions</h3><div>These findings provide real-world evidence on the effectiveness and safety of disease-modifying antirheumatic drugs in a population often excluded from clinical trials, underscoring the need for prospective studies to inform long-term therapeutic decisions.</div></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"21 10","pages":"Article 501995"},"PeriodicalIF":1.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145645940","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-01DOI: 10.1016/j.reuma.2025.501998
Maha S.I. Abdelrahman , Doaa Abdeltawab , Rasha Hamed Shehata
Introduction and objectives
Inflammatory bowel disease (IBD) has systemic consequences that extend beyond the gastrointestinal tract. While nailfold capillaroscopy (NFC) is widely utilized in many rheumatological disorders, its significance in evaluating microvascular changes in IBD remains unknown. This study aimed to standardize NFC use in IBD patients and relate NFC results to clinical and laboratory criteria.
Methods
This observational case–control study included histology- and colonoscopy-diagnosed IBD patients. We performed NFC on eight fingers of each subject using a Dino-Lite digital microscope, adhering to European Alliance of Associations for Rheumatology guidelines. Capillary characteristics, including density, morphology, and dimensions, as well as microhemorrhages, were assessed at 200×.
Results
The study included 50 IBD patients and 30 healthy controls. IBD patients had significantly lower capillary density (7.52 ± 0.68 capillaries/mm) than controls (8.18 ± 0.63 capillaries/mm, p < 0.001), with 26% of IBD patients exhibiting densities below seven capillaries/mm. In IBD patients, microhemorrhages were more prevalent than in controls (p = 0.032). Raynaud's phenomenon was more commonly detected in patients with low mean capillary density (p = 0.04).
Conclusion
IBD patients had reduced mean capillary density and increased microhemorrhages. These changes suggested that NFC could be a non-invasive way provides unique insights into IBD microvascular health.
.
简介和目的炎症性肠病（IBD）具有超越胃肠道的全身性后果。虽然甲襞毛细血管镜（NFC）被广泛应用于许多风湿病，但其在评估IBD微血管变化方面的意义尚不清楚。本研究旨在规范IBD患者NFC的使用，并将NFC结果与临床和实验室标准联系起来。方法本观察性病例对照研究纳入了经组织学和结肠镜诊断的IBD患者。根据欧洲风湿病协会联盟的指导方针，我们使用Dino-Lite数码显微镜对每位受试者的八个手指进行了近距离接触检查。在200x下评估毛细血管特征，包括密度、形态和尺寸，以及微出血。结果本研究包括50例IBD患者和30例健康对照。IBD患者的毛细血管密度（7.52±0.68支/mm）明显低于对照组（8.18±0.63支/mm， p < 0.001）， 26%的IBD患者的毛细血管密度低于7支/mm。在IBD患者中，微出血比对照组更普遍（p = 0.032）。雷诺现象多见于平均毛细血管密度较低的患者（p = 0.04）。结论ibd患者平均毛细血管密度降低，微出血增加。这些变化表明，NFC可能是一种非侵入性的方法，为IBD微血管健康提供了独特的见解。
{"title":"Nailfold capillaroscopy in inflammatory bowel disease: A shared approach in gastroenterology and rheumatology","authors":"Maha S.I. Abdelrahman , Doaa Abdeltawab , Rasha Hamed Shehata","doi":"10.1016/j.reuma.2025.501998","DOIUrl":"10.1016/j.reuma.2025.501998","url":null,"abstract":"<div><h3>Introduction and objectives</h3><div>Inflammatory bowel disease (IBD) has systemic consequences that extend beyond the gastrointestinal tract. While nailfold capillaroscopy (NFC) is widely utilized in many rheumatological disorders, its significance in evaluating microvascular changes in IBD remains unknown. This study aimed to standardize NFC use in IBD patients and relate NFC results to clinical and laboratory criteria.</div></div><div><h3>Methods</h3><div>This observational case–control study included histology- and colonoscopy-diagnosed IBD patients. We performed NFC on eight fingers of each subject using a Dino-Lite digital microscope, adhering to European Alliance of Associations for Rheumatology guidelines. Capillary characteristics, including density, morphology, and dimensions, as well as microhemorrhages, were assessed at 200×.</div></div><div><h3>Results</h3><div>The study included 50 IBD patients and 30 healthy controls. IBD patients had significantly lower capillary density (7.52<!--> <!-->±<!--> <!-->0.68<!--> <!-->capillaries/mm) than controls (8.18<!--> <!-->±<!--> <!-->0.63<!--> <!-->capillaries/mm, <em>p</em> <!--><<!--> <!-->0.001), with 26% of IBD patients exhibiting densities below seven capillaries/mm. In IBD patients, microhemorrhages were more prevalent than in controls (<em>p</em> <!-->=<!--> <!-->0.032). Raynaud's phenomenon was more commonly detected in patients with low mean capillary density (<em>p</em> <!-->=<!--> <!-->0.04).</div></div><div><h3>Conclusion</h3><div>IBD patients had reduced mean capillary density and increased microhemorrhages. These changes suggested that NFC could be a non-invasive way provides unique insights into IBD microvascular health.</div><div>.</div></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"21 10","pages":"Article 501998"},"PeriodicalIF":1.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145645935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-01DOI: 10.1016/j.reuma.2025.502016
Cristóbal Orellana , Silvia Garcia Cirera , Albert Rodrigo Parés , Laia Uriel Brotons , Àlex Arqué Corredor , Cristina Aymerich , Rafael Gómez , Anna Carreras , Antoni Berenguer-Llergo , Joan Calvet
Background
At present, there is a lack of treatments specifically designed to target knee osteoarthritis (KOA). Various intra-articular products have widespread and become commonplace in clinical practice, despite a scarcity of evidence supporting this procedure. Among these, SARC stands out as a novel Autologous Cytokine-Rich Serum derived from the patient's own platelets and white blood cells. This pilot study aims to assess the effectiveness of SARC treatment by measuring improvements in pain and physical disability in patients with symptomatic KOA.
Methods
We recruited 40 symptomatic KOA patients with Kellgren–Lawrence stage 2 or 3, who had been refractory to glucocorticoid intra-articular treatment in the past year. They were assigned to two regimens (single vs. three-dose administrations), and were evaluated for their change in pain and physical function using the KOOS questionnaires at various time points over one year.
Results
At one year after treatment, 36% and 33% of patients achieved a 20% improvement in pain and functional disability, respectively. Patients treated with three intra-articular SARC injections showed a slightly higher improvement (40%) than the single-dose group (26–32%), although differences were not statistically significant. In average, both reversed KOOS scores showed significant improvements compared to baseline, especially for the three-dose group (14 and 16 points, respectively; p-values <0.0001). No adverse events were reported during the study.
Conclusion
A notable proportion of patients with KOA refractory to a previous glucocorticoid injection responded positively to intra-articular SARC treatment. Further studies are required to validate these findings and identify biomarkers of treatment response.
{"title":"A novel Autologous Cytokine-Rich Serum (SARC) to treat knee osteoarthritis patients’ refractory to a previous glucocorticoid intra-articular injection. A pilot study","authors":"Cristóbal Orellana , Silvia Garcia Cirera , Albert Rodrigo Parés , Laia Uriel Brotons , Àlex Arqué Corredor , Cristina Aymerich , Rafael Gómez , Anna Carreras , Antoni Berenguer-Llergo , Joan Calvet","doi":"10.1016/j.reuma.2025.502016","DOIUrl":"10.1016/j.reuma.2025.502016","url":null,"abstract":"<div><h3>Background</h3><div>At present, there is a lack of treatments specifically designed to target knee osteoarthritis (KOA). Various intra-articular products have widespread and become commonplace in clinical practice, despite a scarcity of evidence supporting this procedure. Among these, SARC stands out as a novel Autologous Cytokine-Rich Serum derived from the patient's own platelets and white blood cells. This pilot study aims to assess the effectiveness of SARC treatment by measuring improvements in pain and physical disability in patients with symptomatic KOA.</div></div><div><h3>Methods</h3><div>We recruited 40 symptomatic KOA patients with Kellgren–Lawrence stage 2 or 3, who had been refractory to glucocorticoid intra-articular treatment in the past year. They were assigned to two regimens (single vs. three-dose administrations), and were evaluated for their change in pain and physical function using the KOOS questionnaires at various time points over one year.</div></div><div><h3>Results</h3><div>At one year after treatment, 36% and 33% of patients achieved a 20% improvement in pain and functional disability, respectively. Patients treated with three intra-articular SARC injections showed a slightly higher improvement (40%) than the single-dose group (26–32%), although differences were not statistically significant. In average, both reversed KOOS scores showed significant improvements compared to baseline, especially for the three-dose group (14 and 16 points, respectively; <em>p</em>-values <0.0001). No adverse events were reported during the study.</div></div><div><h3>Conclusion</h3><div>A notable proportion of patients with KOA refractory to a previous glucocorticoid injection responded positively to intra-articular SARC treatment. Further studies are required to validate these findings and identify biomarkers of treatment response.</div></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"21 10","pages":"Article 502016"},"PeriodicalIF":1.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145645936","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-17DOI: 10.1016/j.reuma.2025.501996
Zeineb Meddeb , Nour Ben Younes , Houssem Abida , Hela Boudabous , Mouna Zribi , Cherifa AbdelKefi , Amira El Ouni , Sana Toujani , Safa Khatrouch , Amel Ben Chehida , Kamel Bouslama , Abdelmoula Mohamed Slim , Saloua B’Chir Hamzaoui , Thara Larbi
Introduction and objectives
Gaucher disease (GD) is characterized by an abnormal accumulation of glucocerebroside in the phagocytic cells due to an enzymatic deficiency in glucocerebrosidase. It is a systemic condition frequently associated with skeletal involvement. Our aim was to evaluate bone involvement (BI) in GD and to assess the impact of specific therapies for GD including enzyme replacement therapy (ERT) and substrate reduction therapy (SRT).
Patients and methods
Data at diagnosis and at the final post-treatment follow-up was extracted from the Tunisian GD registry.
Results
Among the 74 included patients 48 had BI (65%), being the third most frequent disease feature. Seventeen patients reported experiencing bone pain crises (23%). Twenty-two patients had elevated alkaline phosphatases (30%), among which, 14 had BI (19%). Standard skeletal X-rays revealed femur deformity in Erlenmeyer flask shape in 4 patients and lytic bone lesions in 2 other patients for whom screening for malignancies was negative. Magnetic resonance imaging of the spine and lower limbs revealed bone marrow infiltration in 19 patients. Aseptic osteonecrosis was identified in 6 patients on MRI (22%). Bone mineral density demonstrated osteoporosis in 7 cases (14%) and osteopenia in 17 others (35%). Specific therapies for GD showed a trend towards improvement of bone pain (velaglucerase alfa) and bone densitometry parameters (velaglucerase alfa and eliglustat) at the final post-treatment follow-up, although formal statistical testing was not feasible due to small and heterogeneous subgroups.
Discussion and conclusions
We presented descriptive data on BI derived from the Tunisian national Gaucher disease registry. This manifestation was common in our cohort. The limited size and heterogeneity of the treated subgroups precluded robust statistical comparisons. A major challenge in our setting is the delayed initiation of specific therapies, primarily due to late diagnosis and limited access to treatment.
{"title":"Bone involvement in Gaucher disease: Data from a North African registry","authors":"Zeineb Meddeb , Nour Ben Younes , Houssem Abida , Hela Boudabous , Mouna Zribi , Cherifa AbdelKefi , Amira El Ouni , Sana Toujani , Safa Khatrouch , Amel Ben Chehida , Kamel Bouslama , Abdelmoula Mohamed Slim , Saloua B’Chir Hamzaoui , Thara Larbi","doi":"10.1016/j.reuma.2025.501996","DOIUrl":"10.1016/j.reuma.2025.501996","url":null,"abstract":"<div><h3>Introduction and objectives</h3><div>Gaucher disease (GD) is characterized by an abnormal accumulation of glucocerebroside in the phagocytic cells due to an enzymatic deficiency in glucocerebrosidase. It is a systemic condition frequently associated with skeletal involvement. Our aim was to evaluate bone involvement (BI) in GD and to assess the impact of specific therapies for GD including enzyme replacement therapy (ERT) and substrate reduction therapy (SRT).</div></div><div><h3>Patients and methods</h3><div>Data at diagnosis and at the final post-treatment follow-up was extracted from the Tunisian GD registry.</div></div><div><h3>Results</h3><div>Among the 74 included patients 48 had BI (65%), being the third most frequent disease feature. Seventeen patients reported experiencing bone pain crises (23%). Twenty-two patients had elevated alkaline phosphatases (30%), among which, 14 had BI (19%). Standard skeletal X-rays revealed femur deformity in Erlenmeyer flask shape in 4 patients and lytic bone lesions in 2 other patients for whom screening for malignancies was negative. Magnetic resonance imaging of the spine and lower limbs revealed bone marrow infiltration in 19 patients. Aseptic osteonecrosis was identified in 6 patients on MRI (22%). Bone mineral density demonstrated osteoporosis in 7 cases (14%) and osteopenia in 17 others (35%). Specific therapies for GD showed a trend towards improvement of bone pain (velaglucerase alfa) and bone densitometry parameters (velaglucerase alfa and eliglustat) at the final post-treatment follow-up, although formal statistical testing was not feasible due to small and heterogeneous subgroups.</div></div><div><h3>Discussion and conclusions</h3><div>We presented descriptive data on BI derived from the Tunisian national Gaucher disease registry. This manifestation was common in our cohort. The limited size and heterogeneity of the treated subgroups precluded robust statistical comparisons. A major challenge in our setting is the delayed initiation of specific therapies, primarily due to late diagnosis and limited access to treatment.</div></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"21 9","pages":"Article 501996"},"PeriodicalIF":1.3,"publicationDate":"2025-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145365780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-15DOI: 10.1016/j.reuma.2025.501969
Beatriz Tejera Segura, Adrián Quevedo Rodriguez, María García González, Judith Hernández Sánchez, Marta Hernández Díaz, Íñigo Rua-Figueroa de Larrinoa
Introduction
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with a variable course. There is a need for simple and accessible biomarkers to assess disease activity and prognosis.
Objectives
To analyze the relationship between hematological indices NLR (neutrophil-to-lymphocyte ratio) and PLR (platelet-to-lymphocyte ratio) with disease activity and organ damage in patients with SLE.
Materials and methods
A multicenter retrospective study including 319 patients with SLE. Associations between NLR and PLR with disease activity (SLEDAI-2K), organ damage (SLICC/SDI), hypocomplementemia, mortality, and clinical manifestations were evaluated.
Results
Both indices showed a significant association with disease activity, even after adjusting for confounding factors. No associations were found with organ damage or specific clinical manifestations. NLR was associated with hypocomplementemia, and both indices were linked to mortality.
Conclusions
NLR and PLR may serve as useful, low-cost, and complementary tools for monitoring disease activity in SLE. Prospective studies are needed to confirm their value as independent biomarkers.
{"title":"Asociación de índices hematológicos, actividad y daño orgánico en el lupus eritematoso sistémico: análisis multicéntrico de 319 casos","authors":"Beatriz Tejera Segura, Adrián Quevedo Rodriguez, María García González, Judith Hernández Sánchez, Marta Hernández Díaz, Íñigo Rua-Figueroa de Larrinoa","doi":"10.1016/j.reuma.2025.501969","DOIUrl":"10.1016/j.reuma.2025.501969","url":null,"abstract":"<div><h3>Introduction</h3><div>Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with a variable course. There is a need for simple and accessible biomarkers to assess disease activity and prognosis.</div></div><div><h3>Objectives</h3><div>To analyze the relationship between hematological indices NLR (neutrophil-to-lymphocyte ratio) and PLR (platelet-to-lymphocyte ratio) with disease activity and organ damage in patients with SLE.</div></div><div><h3>Materials and methods</h3><div>A multicenter retrospective study including 319 patients with SLE. Associations between NLR and PLR with disease activity (SLEDAI-2K), organ damage (SLICC/SDI), hypocomplementemia, mortality, and clinical manifestations were evaluated.</div></div><div><h3>Results</h3><div>Both indices showed a significant association with disease activity, even after adjusting for confounding factors. No associations were found with organ damage or specific clinical manifestations. NLR was associated with hypocomplementemia, and both indices were linked to mortality.</div></div><div><h3>Conclusions</h3><div>NLR and PLR may serve as useful, low-cost, and complementary tools for monitoring disease activity in SLE. Prospective studies are needed to confirm their value as independent biomarkers.</div></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"21 9","pages":"Article 501969"},"PeriodicalIF":1.3,"publicationDate":"2025-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145365706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号